Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.06
12.24
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Tonghua Dongbao Pharmaceutical Co Ltd
Operating Income
Tonghua Dongbao Pharmaceutical Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867
|
Operating Income
¥491.4m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
7%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Operating Income
¥2.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Operating Income
¥3.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
20%
|
CAGR 10-Years
22%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Operating Income
¥5.8B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Operating Income
¥4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
3%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Operating Income
-¥749.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Tonghua Dongbao Pharmaceutical Co Ltd
Glance View
Tonghua Dongbao Pharmaceutical Co., Ltd. is engaged in the manufacture, distribution, research and development of pharmaceuticals. The company is headquartered in Tonghua, Jilin and currently employs 2,814 full-time employees. The firm provides biological products, traditional Chinese medicines and chemical supplements, applied in the treatment of diabetes and cardiovascular and cerebrovascular diseases, among others. The firm's main products portfolio consists of recombinant human insulin bulk drugs and injections, zhennaoning capsules, among others. The firm also provides medical instruments, plastic-steel windows and profiles, and operates property business. The firm distributes its products within domestic markets and to overseas markets.
See Also
What is Tonghua Dongbao Pharmaceutical Co Ltd's Operating Income?
Operating Income
491.4m
CNY
Based on the financial report for Sep 30, 2024, Tonghua Dongbao Pharmaceutical Co Ltd's Operating Income amounts to 491.4m CNY.
What is Tonghua Dongbao Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
7%
Over the last year, the Operating Income growth was -50%. The average annual Operating Income growth rates for Tonghua Dongbao Pharmaceutical Co Ltd have been -28% over the past three years , -13% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet
